Lung cancer: diagnostics flaws are barrier in Spain
This article was originally published in Clinica
The lack of an early and more precise diagnosis of lung cancer is the single most important barrier to dramatically improving survival rates, according to Spanish experts meeting last weekend to discuss the state of care in this area, in preparation for the drafting of new guidelines.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.